Obseva SA (NASDAQ:OBSV) fell 4%despite announcing that the US FDA had accepted its NDA for linzagolix for heavy menses bleeding management related to uterine fibroids in women nearing menopause. Market Stats On Monday, OBSV stock fell 3.88% at $2.23 with more than 6.97 million shares, compared to its average volume of 699k shares. The stock …
Continue reading “Obseva SA (NASDAQ:OBSV) Stock Ends Lower In A Volatile Session After The News”